QuidelOrtho Corporation $QDEL Stake Increased by Fifth Third Bancorp

Fifth Third Bancorp boosted its holdings in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 42,014.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,328 shares of the company’s stock after acquiring an additional 54,199 shares during the quarter. Fifth Third Bancorp owned 0.08% of QuidelOrtho worth $893,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of QDEL. Global Retirement Partners LLC boosted its position in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after purchasing an additional 886 shares during the last quarter. Camelot Portfolios LLC bought a new stake in shares of QuidelOrtho in the 4th quarter valued at approximately $29,000. Hantz Financial Services Inc. grew its stake in shares of QuidelOrtho by 50.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after buying an additional 362 shares in the last quarter. Larson Financial Group LLC increased its holdings in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after buying an additional 1,015 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in QuidelOrtho by 250.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after buying an additional 2,309 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Stock Performance

QuidelOrtho stock opened at $16.05 on Monday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The business’s 50-day simple moving average is $14.87 and its 200-day simple moving average is $18.64. The firm has a market capitalization of $1.09 billion, a PE ratio of -0.90 and a beta of 0.69. QuidelOrtho Corporation has a 52 week low of $9.92 and a 52 week high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same period in the prior year, the firm posted $0.74 EPS. QuidelOrtho’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts forecast that QuidelOrtho Corporation will post 1.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

QDEL has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. Citigroup raised their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Four research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, QuidelOrtho currently has a consensus rating of “Reduce” and an average price target of $13.62.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.